ESR2 and breast cancer: Consistent with established approaches for ERβ knockdown validation in breast cancer cell lines, such as qRT-PCR and Western blot confirmation, we confirmed efficient suppression of ERβ expression in ERβ-modified MDA-MB-231 cells prior to downstream assays [15].